AN2 THERAPEUTICS INC (ANTX) — insider trading
Health Care · NASDAQ
AN2 THERAPEUTICS INC (ANTX) has 46 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase and 11 open-market sales among the most recent 46 (latest 2026-10-12).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-12 | Marks Gilbert Lynn | Director | Grant / award / vesting | 2,283 | — | $0 | Form 4 |
| 2026-10-12 | Martin Patricia A. | Director | Grant / award / vesting | 389 | — | $0 | Form 4 |
| 2026-10-12 | Aziz Kabeer | Director | Grant / award / vesting | 2,465 | — | $0 | Form 4 |
| 2026-09-15 | Trenor Cameron C. III | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 233,333 | — | $0 | Form 4 |
| 2026-09-15 | Trenor Cameron C. III | Officer (Chief Medical Officer) | Grant / award / vesting | 116,667 | — | $0 | Form 4 |
| 2026-09-09 | Readnour Robin Shane | Director | Open-market sale | 585 | $6.02 | $3.5K | Form 4 |
| 2026-09-09 | Readnour Robin Shane | Director | Open-market sale | 523 | $6.02 | $3.2K | Form 4 |
| 2026-09-08 | Readnour Robin Shane | Director | Open-market sale | 5,294 | $6.02 | $31.9K | Form 4 |
| 2026-09-08 | Readnour Robin Shane | Director | Open-market sale | 4,725 | $6.02 | $28.4K | Form 4 |
| 2026-09-03 | Readnour Robin Shane | Director | Open-market sale | 3,223 | $6.07 | $19.6K | Form 4 |
| 2026-09-03 | Readnour Robin Shane | Director | Open-market sale | 2,877 | $6.07 | $17.5K | Form 4 |
| 2026-09-01 | Williams Sarah Joanne | Officer (Principal Accounting Officer) | Open-market sale | 272 | $5.53 | $1.5K | Form 4 |
| 2026-09-01 | FitzPatrick Margaret M | Director | Open-market purchase | 2,098 | $5.53 | $11.6K | Form 4 |
| 2026-08-17 | Readnour Robin Shane | Director | Open-market sale | 18,706 | $6.01 | $112.4K | Form 4 |
| 2026-08-17 | Readnour Robin Shane | Director | Open-market sale | 16,696 | $6.01 | $100.3K | Form 4 |
| 2026-08-14 | Zakrzewski Joseph S | Director | Bona fide gift | 405,880 | — | $0 | Form 4 |
| 2026-07-10 | Martin Patricia A. | Director | Grant / award / vesting | 766 | — | $0 | Form 4 |
| 2026-07-10 | Marks Gilbert Lynn | Director | Grant / award / vesting | 2,789 | — | $0 | Form 4 |
| 2026-07-10 | Aziz Kabeer | Director | Grant / award / vesting | 2,852 | — | $0 | Form 4 |
| 2026-07-08 | Eizen Joshua M | Officer (See Remarks) | Open-market sale | 5,945 | $4.17 | $24.8K | Form 4 |
| 2026-05-29 | Williams Sarah Joanne | Officer (Principal Accounting Officer) | Open-market sale | 265 | $4.43 | $1.2K | Form 4 |
| 2026-04-10 | Martin Patricia A. | Director | Grant / award / vesting | 1,192 | — | $0 | Form 4 |
| 2026-04-10 | Marks Gilbert Lynn | Director | Grant / award / vesting | 3,775 | — | $0 | Form 4 |
| 2026-04-10 | Aziz Kabeer | Director | Grant / award / vesting | 3,775 | — | $0 | Form 4 |
| 2026-03-19 | Aziz Kabeer | Director | Disposition to the issuer (derivative) | 23,742 | — | — | Form 4 |
| 2026-03-19 | Aziz Kabeer | Director | Grant / award / vesting (derivative) | 23,742 | — | — | Form 4 |
| 2026-03-19 | Aziz Kabeer | Director | Disposition to the issuer (derivative) | 20,724 | — | — | Form 4 |
| 2026-03-19 | Aziz Kabeer | Director | Grant / award / vesting (derivative) | 20,724 | — | — | Form 4 |
| 2026-03-19 | Marks Gilbert Lynn | Director | Disposition to the issuer (derivative) | 23,742 | — | — | Form 4 |
| 2026-03-19 | Marks Gilbert Lynn | Director | Grant / award / vesting (derivative) | 23,742 | — | — | Form 4 |
| 2026-03-19 | Marks Gilbert Lynn | Director | Disposition to the issuer (derivative) | 10,362 | — | — | Form 4 |
| 2026-03-19 | Marks Gilbert Lynn | Director | Grant / award / vesting (derivative) | 10,362 | — | — | Form 4 |
| 2026-03-19 | Marks Gilbert Lynn | Director | Disposition to the issuer (derivative) | 10,665 | — | — | Form 4 |
| 2026-03-19 | Marks Gilbert Lynn | Director | Grant / award / vesting (derivative) | 10,665 | — | — | Form 4 |
| 2026-03-19 | Chanda Sanjay | Officer (Chief Development Officer) | Disposition to the issuer (derivative) | 41,665 | — | — | Form 4 |
| 2026-03-19 | Chanda Sanjay | Officer (Chief Development Officer) | Grant / award / vesting (derivative) | 41,665 | — | — | Form 4 |
| 2026-03-19 | Chanda Sanjay | Officer (Chief Development Officer) | Disposition to the issuer (derivative) | 57,950 | — | — | Form 4 |
| 2026-03-19 | Chanda Sanjay | Officer (Chief Development Officer) | Grant / award / vesting (derivative) | 57,950 | — | — | Form 4 |
| 2026-03-19 | Chanda Sanjay | Officer (Chief Development Officer) | Disposition to the issuer (derivative) | 66,000 | — | — | Form 4 |
| 2026-03-19 | Chanda Sanjay | Officer (Chief Development Officer) | Grant / award / vesting (derivative) | 66,000 | — | — | Form 4 |
| 2026-03-19 | Day Lucy | Officer (Chief Financial Officer) | Disposition to the issuer (derivative) | 82,300 | — | — | Form 4 |
| 2026-03-19 | Day Lucy | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 82,300 | — | — | Form 4 |
| 2026-03-19 | Day Lucy | Officer (Chief Financial Officer) | Disposition to the issuer (derivative) | 66,000 | — | — | Form 4 |
| 2026-03-19 | Day Lucy | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 66,000 | — | — | Form 4 |
| 2026-03-19 | Day Lucy | Officer (Chief Financial Officer) | Disposition to the issuer (derivative) | 73,665 | — | — | Form 4 |
| 2026-03-19 | Day Lucy | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 73,665 | — | — | Form 4 |
Ask the chat about ANTX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: AN2 THERAPEUTICS INC (ANTX).
Last updated 2026-10-12 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.